Australia markets closed

Algorae Pharmaceuticals Limited (LVCLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.00410.0000 (0.00%)
At close: 01:47PM EDT

Algorae Pharmaceuticals Limited

Rialto South Tower
Level 23 525 Collins Street
Melbourne, VIC 3000
61 2 9698 5414

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. David Richard HainsworthCEO & Executive Chairman25.76kN/A1974
Mr. Daya Uka B.Com., C.A.Chief Financial Officer98.57kN/AN/A
Dr. Belinda Di BartoloChief Operations Officer117.4kN/AN/A
Dr. Carolyn M. Sue A.M., B.S., Ph.D.Member of Medical Advisory Board & Chief Medical Officer of NTCELL32.2kN/A1963
Dr. James A. MckennaChief Scientific OfficerN/AN/AN/A
Ms. Leah PierisCompany SecretaryN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Algorae Pharmaceuticals Limited, a biotechnology company, focuses on developing solutions for Parkinson's disease in Australia. It is developing NTCELL, an alginate coated capsule to target the treatment of Parkinson's disease; and AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient treatment for dementia, including Alzheimer's disease. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. The company was founded in 1987 and is based in Melbourne, Australia.

Corporate governance

Algorae Pharmaceuticals Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.